---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-000801"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:05:26.695193+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pieris receives $5M milestone from Seagen for Phase 1 start of CD228 x 4-1BB bispecific SGN-BB228

## Summary
- Achieved $5M milestone from Seagen upon first patient dosed in Phase 1 study of SGN-BB228 (PRS-346).
- Phase 1 trial (NCT05571839) evaluates SGN-BB228 in advanced melanoma and other solid tumors.
- This is the first clinical start in Pieris' collaboration with Seagen; two additional programs ongoing.
- Pieris has an opt-in option for U.S. co-promotion on one program in the collaboration.

## SEC filing metadata
- accession: 0001437749-23-000801
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/0001437749-23-000801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774923000801/pirs20230110c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-000801
- JSON: https://secwatch.observer/filing/0001437749-23-000801.json
- Plain text: https://secwatch.observer/filing/0001437749-23-000801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.